Skip to main content

Advertisement

SpringerLink
Log in

Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors

Guideline Drafting Committee for Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine

  • Others
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Since the 1980s when clinical therapeutic trials were initiated, 131I-MIBG radiotherapy has been used in foreign countries for unresectable neuroendocrine tumors including malignant pheochromocytomas and neuroblastomas. In Japan, 131I-MIBG radiotherapy has not been approved by the Ministry of Health, Labour and Welfare; however, personally imported 131I-MIBG is now available for therapeutic purposes in a limited number of institutions. These updated draft guidelines aim to provide useful information concerning 131I-MIBG radiotherapy, to help prevent side effects and protect physicians, nurses, other health care professionals, patients and their families from radiation exposure. The committee has also provided appendices on topics such as practical guidance for attending physicians, patient management, and referring physicians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nakajo M, Yoshinaga K, Oriuchi N, Kinuya S, Yokoyama K, Yamaguchi T, et al. Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors. Kaku igaku Jpn J Nucl Med. 2008;45(1):1–40.

    Google Scholar 

  2. Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, et al. Effects and safety of I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J. 2014.

  3. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer. 2002;94(7):2081–9.

    Article  PubMed  Google Scholar 

  4. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011;56(2):191–201.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Shapiro B. Summary, conclusions, and future directions of [131I] metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med. 1991;35(4):357–63.

    CAS  PubMed  Google Scholar 

  6. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med Off Publ Soc Nucl Med. 1984;25(2):197–206.

    CAS  Google Scholar 

  7. Pujol P, Bringer J, Faurous P, Jaffiol C. Metastatic phaeochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy. Eur J Nucl Med. 1995;22(4):382–4.

    Article  CAS  PubMed  Google Scholar 

  8. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20(11):648–58.

    Article  CAS  PubMed  Google Scholar 

  9. Troncone L, Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med Off Publ Ital Assoc Nucl Med. 1999;43(4):344–55.

    CAS  Google Scholar 

  10. Chatal JF, Hoefnagel CA. Radionuclide therapy. Lancet. 1999;354(9182):931–5.

    Article  CAS  PubMed  Google Scholar 

  11. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol. 2001;55(1):47–60.

    Article  CAS  Google Scholar 

  12. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134(6):956–62 (discussion 962–3).

    Article  PubMed  Google Scholar 

  13. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol Eur Fed Endocr Soc. 2004;151(1):15–27.

    Article  CAS  Google Scholar 

  14. Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma: implications for therapy. Ann N Y Acad Sci. 2006;1073:505–11.

    Article  CAS  PubMed  Google Scholar 

  15. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. 2006;1073:465–90.

    Article  CAS  PubMed  Google Scholar 

  16. Troncone L, Rufini V. 131I-MIBG therapy of neural crest tumours (review). Anticancer Res. 1997;17(3B):1823–31.

    CAS  PubMed  Google Scholar 

  17. Shapiro B. A review of the status of radio-iodinated-MIBG therapy for neuroendocrine tumors. Intern Med. 1994;2:61–8.

    Google Scholar 

  18. Castellani MR, Chiti A, Seregni E, Bombardieri E. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med Off Publ Ital Assoc Nucl Med. 2000;44(1):77–87.

    CAS  Google Scholar 

  19. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001;8(2):135–47.

    Article  CAS  PubMed  Google Scholar 

  20. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(6):1829–38.

    CAS  Google Scholar 

  21. Voute PA, Hoefnagel CA, de Kraker J, Evans AE, Hayes A, Green A. Radionuclide therapy of neural crest tumors. Med Pediatr Oncol. 1987;15(4):192–5.

    Article  CAS  PubMed  Google Scholar 

  22. Garaventa A, Guerra P, Arrighini A, Bertolazzi L, Bestagno M, De Bernardi B, et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer. 1991;67(4):922–8.

    Article  CAS  PubMed  Google Scholar 

  23. Mastrangelo R, Tornesello A, Mastrangelo S. Position paper role of 131I-Metaiodobenzylguanitidine in the treatment of neuroblastoma. Med Pediatr Oncol. 1988;31:22–6.

    Article  Google Scholar 

  24. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med Off Publ Soc Nucl Med. 2001;42(11):1713–21.

    CAS  Google Scholar 

  25. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003;25(7):543–7.

    Article  PubMed  Google Scholar 

  26. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(9):1054–60.

    Article  CAS  Google Scholar 

  27. Aritake S. Radioisotope therapy of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine–absorbed dose assessments using SPECT. Kaku igaku Jpn J Nucl Med. 1992;29(6):667–78.

    CAS  Google Scholar 

  28. Nakabeppu Y, Nakajo M. Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG. Ann Nucl Med. 1994;8(4):259–68.

    Article  CAS  PubMed  Google Scholar 

  29. Tristam M, Alaamer AS, Fleming JS, Lewington VJ, Zivanovic MA. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. J Nucl Med Off Publ Soc Nucl Med. 1996;37(6):1058–63.

    CAS  Google Scholar 

  30. Guidelines for 131I-meta-iodobenzylguanidine therapy. Eur J Nucl Med Mol Imaging 2003;30(3):BP23–BP26.

  31. Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging. 2002;29(12):1581–7.

    Article  CAS  PubMed  Google Scholar 

  32. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, et al. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003;98(2):239–48.

    Article  CAS  PubMed  Google Scholar 

  33. Monsieurs MA, Thierens HM, Vral A, Brans B, De Ridder L, Dierckx RA. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun. 2001;22(4):367–74.

    Article  CAS  PubMed  Google Scholar 

  34. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(3):500–6.

    Article  CAS  Google Scholar 

  35. Okazawa H, Endo K, Saga T, Watanabe Y, Nakai T, Sasaki K, Konishi Z, Abe K. Therapy of malignant pheochromoacytoma using I-131 metaiodbenzylguanitidine. JJR. 1989;50 (3):286–294.

  36. Furusawa M, Shimomura O, Tomiguchi S, Hirota Y, Takahashi M, Yamauchi J, et al. Radionuclide therapy of Sipple syndrome using iodine-131 metaiodobenzylguanidine. Kaku igaku Jpn J Nucl Med. 1992;29(9):1133–8.

    CAS  Google Scholar 

  37. Sakahara H, Endo K, Saga T, Hosono M, Kobayashi H, Konishi J. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma. Ann Nucl Med. 1994;8(2):133–7.

    Article  CAS  PubMed  Google Scholar 

  38. Tsukamoto EYK, Tamaki N. Current status of 131 I-MIBG therapy and future direction. Mon J Med Imaging Inf. 2001;33:1076–1080.

  39. Kusakabe K, Kanaya K, Kanaya S, Yazaki E, Nakano K, Matsumoto N, et al. Therapeutic effectiveness of 131I-MIBG on malignant pheochromocytoma–results of long-term follow-up. Kaku igaku Jpn J Nucl Med. 1994;31(12):1495–502.

    CAS  Google Scholar 

  40. Prvulovich EM, Stein RC, Bomanji JB, Ledermann JA, Taylor I, Ell PJ. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases. J Nucl Med Off Publ Soc Nucl Med. 1998;39(10):1743–5.

    CAS  Google Scholar 

  41. Brogsitter C, Pinkert J, Bredow J, Kittner T, Kotzerke J. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. J Nucl Med Off Publ Soc Nucl Med. 2005;46(12):2112–6.

    CAS  Google Scholar 

  42. Zuetenhorst H, Taal BG, Valdes Olmos R, Hoefnagel C, Boot H. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol. 1999;11(10):1157–64.

    Article  CAS  PubMed  Google Scholar 

  43. Taal BG, Hoefnagel C, Boot H, Valdes Olmos R, Rutgers M. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol Off J Eur Soc Med Oncol ESMO 2000;11(11):1437–43.

  44. Mastrangelo S, Tornesello A, Diociaiuti L, Riccardi R, Rufini V, Troncone L. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma. Q J Nucl Med Off Publ Ital Assoc Nucl Med. 1995;39(4 Suppl 1):69–71.

    CAS  Google Scholar 

  45. Voute PA, van der Kleij AJ, De Kraker J, Hoefnagel CA, Tiel-van Buul MM, Van Gennip H. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer. 1995;31A(4):596–600.

  46. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med Off Publ Ital Assoc Nucl Med. 1999;43(4):336–43.

    CAS  Google Scholar 

  47. Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V, et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer. 2001;84(4):460–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Hoefnagel CA, De Kraker J. Valdes Olmos RA, Voute PA. 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun. 1994;15(9):712–7.

    Article  CAS  PubMed  Google Scholar 

  49. De Kraker J, Hoefnagel CA, Caron H, Valdes Olmos RA, Zsiros J, Heij HA, et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer. 1995;31A(4):600–2.

    Article  PubMed  Google Scholar 

  50. Hoefnagel CA, De Kraker J, Valdes Olmos RA, Voute PA. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med Off Publ Ital Assoc Nucl Med. 1995;39 (4 Suppl 1):61–4.

  51. De Kraker J, Hoefnagel CA, Caron HN, Vos A, Bras J, Greve JC. Iodobenzylguanide-131 therapy as first choice in non-metastasized neuroblastoma. Ned Tijdschr Geneeskd. 1996;140(40):1997–2000.

    PubMed  Google Scholar 

  52. Takagi S, Tanabe A. Hypertensive crisis, manual of tests for endocrine diseases, manual for emergent endocrine symptoms. Jpn Med J. 2006;196.

  53. Naruse M. Pheochromocytoma, guidebook for specialists in endocrine and metabolic diseases. Tokyo: Shindan to Chiryosha Inc; 2006.

    Google Scholar 

  54. Manger M, Ray W. Clinical and experimental pheochromocytoma. 2nd edition, illustrated. Cambridge, Mass: Blackwell Science; 1996.

  55. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. Eanm. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35(5):1039–47.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Faculty of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

    Seigo Kinuya

  2. Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Keiichiro Yoshinaga

  3. Molecular Imaging Research Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-Ku, Chiba, 263-8555, Japan

    Keiichiro Yoshinaga

  4. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan

    Tetsuya Higuchi

  5. Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    Megumi Jinguji

  6. Department of Radiology, National Cancer Research Institute, Tokyo, Japan

    Hiroaki Kurihara & Hiroshi Kawamoto

  7. Department of Pediatric Oncology, National Cancer Research Institute, Tokyo, Japan

    Hiroaki Kurihara & Hiroshi Kawamoto

Authors
  1. Seigo Kinuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keiichiro Yoshinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megumi Jinguji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroaki Kurihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Kawamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keiichiro Yoshinaga.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kinuya, S., Yoshinaga, K., Higuchi, T. et al. Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors. Ann Nucl Med 29, 543–552 (2015). https://doi.org/10.1007/s12149-015-0960-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-015-0960-z

Keywords

Search

Navigation